Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes
|
|
- Ilene Gregory
- 6 years ago
- Views:
Transcription
1 Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant for the following organizations: Novo Nordisk Lilly Sanofi Janssen 1
2 Diabetes Mellitus in the US 29.1 million Americans have diabetes (2012) 9.3% of the population 86 million Americans age 20 and older have prediabetes 7 th leading cause of death in US 8.1 million Americans with Diabetes are undiagnosed In seniors (age 65 and older) the prevalence is 25.9% 1.4 million new diagnosis annually American Diabetes Association: basics/statistics/ (Accessed 9/7/2016) Oral Antihyperglycemic Agents empagliflozin alogliptin metformin repaglinide glyburide glimepiride dapagliflozin miglitol Are you feeling confused with all of the choices bromocriptine in diabetes medications? pioglitazone saxagliptin linagliptin sitagliptin glipizide acarbose colesevelam rosiglitazone nateglinide canagliflozin 2
3 HTN and Diabetes Drug Classes in the US over the past 90 Years Number of Medication Classes Diuretics Adrenergic neuronal blockers Sulfonylureas Vasodialators Peripheral -1 Blockers ACE Inhibitors Central -2 Agonists (Phenformin) Withdrawn 1978 Amylinomimetics Calcium Channel Blockers -blockers Angiotensin II Receptor Blockers Thiazolidinediones Renin Inhibitors -glucosidase Inhibitors Biguanides GLP-1 Receptor Agonists Meglitinides Dopamine Agonists Bile Acid Sequestrants DPP-4 Receptor Antagonists SGLT-2 Inhibitors 1920 s 1950 s 1960 s 1970 s 1980 s 1990 s 2000 s 2010 s Spheres of Concern Hypoglycemia CV Risk Reduction Renal/UTI/Genital Patient Weight Economic Gastrointestinal 3
4 Do Patients Come to You: Excited? Happy? Committed? Hopeful? Fearful? Hesitant? Dreading? What can we do to improve this? When Patients Come to You: The Words We Use Can Have a Mighty Impact. Our Body Language Tells More Than Our Words. 4
5 When Patients Come to You: Leave Some Hope With The Patient. Never Say Never. Work With The Patient s Priorities Healthy eating, wt. control, increased physical activity & diabetes education American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. Diabetes Self Management Education improved diabetes knowledge improved self care behavior improved clinical outcomes lower A1C lower self reported weight improved quality of life healthy coping lower costs American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S20 S21. 5
6 Approaches to Glycemic Treatment Pharmacological Therapy for Type 2 DM is preferred if tolerated and not contraindicated Consider if symptomatic or blood sugars high Advance therapy q3 months if not at goal Patient centered approach to therapy T2DM is progressive. therapy will eventually be needed in most cases American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. 6
7 Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy Hypo Risk.. Weight.... Side Effects... Cost. Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor High.. high. Intermediate.. Intermediate.. high.. Agonist Moderate risk. low Risk.. Low risk.. Low risk Low risk gain... Gain. neutral.. losing losing.. hypoglycemia. Edema,CHF,Fx s Low rare GU, dehydration. GI.. Low. high high high (basal) Highest High risk gain hypoglycemia variable If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy. Hypo Risk. Weight.. Side Effects. Cost Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor High.. high. Intermediate.. Intermediate.. high.. Agonist Moderate risk. low Risk.. Low risk.. Low risk Low risk gain... Gain. neutral.. losing losing.. hypoglycemia. Edema,CHF,Fx s rare GU, dehydration. GI.. Low. Low Cost high high high (basal) Highest High risk gain hypoglycemia variable American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor Agonist (basal) If A1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables; (2) on GLP RA, add basal insuin; or (3) on optimally titrated basal insulin, add or mealtime insulin. In refractory patients, consider adding or SGLT 2i: 7
8 Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy. Hypo Risk. Weight.. Side Effects. Cost Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor High.. high. Intermediate.. Intermediate.. high.. Agonist Moderate risk. low Risk.. Low risk.. Low risk Low risk gain... Gain. neutral.. losing losing.. hypoglycemia. Edema,CHF,Fx s rare GU, dehydration. GI.. Low. Low Cost high high high (basal) Highest High risk gain hypoglycemia variable American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor Agonist (basal) If A1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables; (2) on GLP RA, add basal insuin; or (3) on optimally titrated basal insulin, add or mealtime insulin. In refractory patients, consider adding or SGLT 2i: (basal) Mealtime or Garber AJ et al. Endocr Pract. 2013;19(Suppl 2):1 48. Garber AJ, AJ, et et al. al. Endocr Pract. 2015;21(4):
9 Things Patients Never Say: Doc, My I Diabetes Algorithm is Off. My seldom Grandmother Can LDL Cholesterol You use Fix my It? insulin. and Hurts Uncle I don t had a exercise horrible and painful I eat death odd as hours. a result Can of their diabetes Life as you I know and fix me? I it am is over..right? afraid this will happen to me. New Therapeutic Classes 9 classes of oral medication 4 classes of subcutaneous medications New Concentrated s /GLP 1 Combinations New classes coming.. 9
10 Where Diabetes Medications Work GLP 1 GLP 1 GLP 1 GLP 1 GLP 1 DeFronzo RA. Diabetes. 2009;58 (4): Where Diabetes Medications Work GLP 1 GLP 1 GLP 1 GLP 1 GLP 1 DeFronzo RA. Diabetes. 2009;58 (4):
11 Class Generic Name Trade Name α glucosidase Inhibitor acarobose, miglitol Precose, Glyset amylinomimetics amylin Symlin biguanides metformin Glucophage, Riomet Bile Acid Sequestrants colesevelam WelChol Dopamine Agonists bromocriptine Cycloset DPP 4i GLP 1 Agonists alogliptin, linagliptin saxagliptin, sitagliptin albiglutide, dulaglutide exenatide, liraglutide Nesina, Tradjenta Onglyza, Januvia Tanzeum, Trulicity, Byetta Victoza Glucagon glucagon Glucagon meglitinides SGLT 2i Sulfonylureas insulin (various) nateglinide, repaglinide canagliflozin, dapagliflozin, empagliflozin glimepiride, glipizide glyburide Humulin, Novolin, Humalog, Novolog, Apidra, Lantus, Levemir Starlix, Prandin Invokana, Farxiga, Jardiance Amaryl, Glucotrol, Diabeta, Micronase Thiazolidinediones pioglitazone, rosiglitazone asdf Actos, Avandia Oral Diabetes Medications Secretion Hepatic Glucose Production Pancreatic Glucagon Secretion Peripheral Glucose Uptake GI CHO Absorption Renal Reabsorp-tion of Glucose β-cell Function -Glucosidase Inhibitor Biguanide Bromocriptine Colesevelam Unknown Unknown DPP-4 Inhibitor Improve * Glinide SGLT-2 Inhibitor Improve National Diabetes Education Program. Available at: Accessed August 10, Nathan DM, et al. Diabetes Care. 2009;32: Rodbard HW, et al. Endocr Pract. 2009;15(6): Januvia [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; Onglyza [prescribing information]. Princeton, NJ: Bristol Myers Squibb Co.; Welchol [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc.; Cycloset [prescribing information]. San Diego, CA: Santarus, Inc.; * In vitro and rodent data; preliminary human data 11
12 Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy. Hypo Risk. Weight.. Side Effects. Cost Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor High.. high. Intermediate.. Intermediate.. high.. Agonist Moderate risk. low Risk.. Low risk.. Low risk Low risk gain... Gain. neutral.. losing losing.. hypoglycemia. Edema,CHF,Fx s rare GU, dehydration. GI.. Low. Low Cost high high high (basal) Highest High risk gain hypoglycemia variable American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor Agonist (basal) If A1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables; (2) on GLP RA, add basal insuin; or (3) on optimally titrated basal insulin, add or mealtime insulin. In refractory patients, consider adding or SGLT 2i: (basal) Mealtime or The Incretin System 12
13 Multiple Sites of Actions of Incretins Hormone that stimulates insulin secretion in response to oral carbohydrate intake GLP 1 GIP This action impacts multiple sites of glucose regulation Suppression of glucagon at the pancreatic cell Stimulates insulin release at the pancreatic cell Promotes satiety and reduce appetite in CNS Slows gastric emptying nactivates native GLP 1 Works quickly Current Stable of GLP 1 agonists Twice Daily Exenatide Lixisenatide (FDA Approved 7/28/2016) 1 Once Daily Liraglutide Once Weekly Albiglutide Dulaglutide Exenatide LAR Semaglutide (oral) (Investigational) 1. FDA Press Release: (Accessed 9/18/2016) 13
14 Current Stable of GLP 1 agonists Generic Name Albiglutide Exenatide IR Exenatide LAR Dulaglutide Liraglutide Lixisenatide Dosage Expected A1c Reduction Fasting BGM Reduction 30 mg/wk 0.7% 16 mg/dl 50 mg/wk 0.9% 25 mg/dl % Patients Reaching <7% A1c 5 mcg/bid 0.7% 17 mg/dl 48% 10 mcg BID 0.9% 19 mg/dl 53% 2 mg subq weekly 1.6% 25 mg/dl 58% 0.75 mg/weekly 0.7% 26 mg/dl 1.5 mg/weekly 0.8% 29 mg/dl 1.2 mg/d 0.8% 15 mg/dl 1.8 mg/d 1.1% 26 mg/dl 10 mcg/d Transition Dose 20 mcg/d 0.83% mg/dl 44% PI MG IFU COMBINED.PDF Current Stable of GLP 1 agonists Generic Name Albiglutide (Tanzeum) Exenatide IR (Byetta) Exenatide LAR (Bydureon) Dulaglutide (Trulicity) Liraglutide (Victoza) Lixisenatide (Adlyxin) Dosage Expected A1c Reduction Fasting BGM Reduction 30 mg/wk 0.7% 16 mg/dl 50 mg/wk 0.9% 25 mg/dl % Patients Reaching <7% A1c 5 mcg/bid 0.7% 17 mg/dl 48% 10 mcg BID 0.9% 19 mg/dl 53% 2 mg subq weekly 1.6% 25 mg/dl 58% 0.75 mg/weekly 0.7% 26 mg/dl 1.5 mg/weekly 0.8% 29 mg/dl 1.2 mg/d 0.8% 15 mg/dl 1.8 mg/d 1.1% 26 mg/dl 10 mcg/d Transition Dose 20 mcg/d 0.83% mg/dl 44% PI MG IFU COMBINED.PDF 14
15 Risks: GLP 1 s and Safety GI upset: Nausea, Vomiting, Diarrhea Pancreatitis Renal Impairment Medullary Thyroid Carcinoma (Rats and Mice) Hypersensitivity Hypoglycemia (esp. with insulin and sulfonylureas) GLP 1 s and Safety Choosing the Right Patient: Exclusions Personal Hx of Pancreatitis or high risk of developing pancreatitis Gastroparesis Severe Renal Disease Personal or Family Hx of Medullary Thyroid Carcinoma Personal or Family Hx of MEN 2 (thyroid, parathyroid and adrenal tumors) 15
16 Current Basal s 16
17 How Do You Approach The Discussion? is a 4 letter word Patients: Can be injection adverse Fearful of losing control of life and scheduling Fearful of the End of the Road The Unknown Use All of Your Resources Healthy eating, wt. control, increased physical activity & diabetes education Efficacy Hypo Risk.. Weight.... Side Effects... Cost. High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy. Hypo Risk. Weight.. Side Effects. Cost Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor High.. high. Intermediate.. Intermediate.. high.. Agonist Moderate risk. low Risk.. Low risk.. Low risk Low risk gain... Gain. neutral.. losing losing.. hypoglycemia. Edema,CHF,Fx s rare GU, dehydration. GI.. Low. Low Cost high high high (basal) Highest High risk gain hypoglycemia variable American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor Agonist (basal) If A1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables; (2) on GLP RA, add basal insuin; or (3) on optimally titrated basal insulin, add or mealtime insulin. In refractory patients, consider adding or SGLT 2i: (basal) Mealtime or 17
18 Current Basal s Once Daily Degludec 1 U 100 U 200 Detemir 2 U 100 Glargine 3,4 U 100 U 300 Twice Daily Detemir 2 U 100 (NPH 5 ) U pi.com/tresiba.pdf (Accessed 9/30/2016) 2. pi.com/levemir.pdf (Accessed 9/30/2016) 3. (Accessed 9/30/2016) 4. (Accessed 9/30/2016) 5. N USPI.pdf (Accessed 9/30/2016) Current Basal s Generic Name Concentration Expected A1c Reduction Fasting BGM Reduction Degludec 1 U % 16 mg/dl U % 25 mg/dl Detemir 2 U % 69 mg/dl Glargine U % 49 mg/dl U % 29 mg/dl (NPH) (typically twice daily dosing) 5 U pi.com/tresiba.pdf (Accessed 9/30/2016) 2. pi.com/levemir.pdf (Accessed 9/30/2016) 3. (Accessed 9/30/2016) 4. (Accessed 9/30/2016) 5. N USPI.pdf (Accessed 9/30/2016) 18
19 Current Basal s Generic Name Degludec 1 (Tresiba) Detemir 2 (Levemir) Glargine (Lantus, Toujeo) Concentration Expected A1c Reduction Fasting BGM Reduction U % 16 mg/dl U % 25 mg/dl U % 69 mg/dl U % 49 mg/dl U % 29 mg/dl (NPH) (typically twice daily dosing) 5 (Novolin, Humulin) U pi.com/tresiba.pdf (Accessed 9/30/2016) 2. pi.com/levemir.pdf (Accessed 9/30/2016) 3. (Accessed 9/30/2016) 4. (Accessed 9/30/2016) 5. N USPI.pdf (Accessed 9/30/2016) s in General Robust blood sugar reduction A1c reductions % Few toxicities Hypersensitivities typically related to excipients Hypoglycemia requires monitoring and management Antibodies clinical significance? Lipodystrophy Edema Few Drug:Drug interactions Most are changes in blood sugars, high or low Delivery Vial/Syringe Pens Pumps Inhalation 19
20 Safety and Basal Hypoglycemia Especially when combined with secretogogues ( s, glinides) Hypersensitivity Weight Gain Pen Sharing! Inappropriate Dosing Mixing s Mis Dosing Why the New s? Flatter Action Curves Prolonged Activity Smaller Depot Suggestion of improved nocturnal hypoglycemia 20
21 Confirmed Nocturnal or Severe Nocturnal Hypoglycemic Events (Weeks 9 to 6 months) Gla 300 % (Events/pt yr) Gla 100 %(Events/pt yr) Relative Risk [95%CI] Based on % pts. Edition 1 Edition 2 Edition (2.97) 21.6 (1.94) 16 (NS) 45.8 (4.05) 27.9 (3.19) 17 (NS) 0.79 [0.67,0.93]* 0.77 [0.61,0.99]* 0.89 [0.66,1.20] *Significant vs. Gla 100 % = percentage of patients experiencing 1 event, NS = not shown (Accessed 10/1/2016) Confirmed Nocturnal Hypoglycemic (Meta analysis): Degludec End of Trial Rate Ratio IDeg vs. GLA [95%CI] Dose Titration Period Maintenance Period T2D Pooled Studies 0.68 [0.57, 0.82]* 0.81 [0.64,1.02] 0.62 [0.49, 0.78]* T1D Pooled Studies 0.83 [0.69, 1.00] 0.88 [0.72, 1.08] 0.75 [0.60, 0.94]* T2D and T1D Pooled Studies 0.75 [0.65, 0.85]* 0.86 [0.74, 1.00] 0.68 [0.58, 0.80]* *Significant vs. Gla (Accessed 10/1/2016) Russel Jones, et al. Nutrition Metab Cardiovasc Dis;
22 10/28/2016 Healthy eating, wt. control, increased physical activity & diabetes education High Efficacy Low Hypoglycemic Risk Weight Neutral Lactic Acidosis/GI intolerance Low Cost Efficacy Hypo Risk.. Weight.... Side Effects... Cost. If A1c target not achieved after ~3 months of monotherapy, proceed to 2 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). Efficacy. Hypo Risk. Weight.. Side Effects. Cost Sulfonylurea High.. Moderate risk. gain... hypoglycemia. Low. Thiazolidinedione high. low Risk.. Gain. Edema,CHF,Fx s Low Cost DPP 4 Inhibitor Intermediate.. Low risk.. neutral.. rare high SGLT 2 Inhibitor Intermediate.. Low risk losing GU, dehydration. high GLP 1 Receptor Agonist high.. Low risk losing.. GI.. high (basal) Highest High risk gain hypoglycemia variable If A1c target not achieved after ~3 months of dual therapy, proceed to 3 drug combination (order not meant to denote any specific preference choice dependent on a variety of patient and disease specific factors). American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes Diabetes Care 2015;38(Suppl. 1):S41 S48. Sulfonylurea Thiazolidinedione DPP 4 Inhibitor SGLT 2 Inhibitor GLP 1 Receptor Agonist (basal) If A1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables; (2) on GLP RA, add basal insuin; or (3) on optimally titrated basal insulin, add or mealtime insulin. In refractory patients, consider adding or SGLT 2i: (basal) Mealtime or 22
23 Rationale for Basal /GLP 1 Balanced Approach to Fasting and Prandial glucose coverage Replace insulin for fasting/underlying glycemic control Up regulating native gut metabolism to glucose stimulation Easier for patient than MDI insulin management Overall reduced risk of hypoglycemia vs. MDI Where Diabetes Medications Work GLP 1 GLP 1 GLP 1 GLP 1 GLP 1 DeFronzo RA. Diabetes (4):
24 Effect of Glargine Up Titration vs. Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial Baseline A1c = 8.4% 767 Pts Screened 557 Randomized Baseline A1c = 8.2% 278 Received Degludec/liraglutide 279 Received insulin glargine metformin 250 participants completed 265 participants completed A1c = 1.81% Wt = 1.4kg Hypoglycemia 2.23 episodes/pt. year A1c <7% = 71.6% A1c = 1.13% Wt = 1.8kg Hypoglycemia 5.05 episodes/pt. year A1c <7% = 24.6% 26 Week Study Period Randomized, open label, treat to target Lingvay I, Manghi F et. al. Effect of Glargine UP titration vs Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes. JAMA. 2016;315: Effect of Glargine Up Titration vs. Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial Lingvay I, et al. Effect of Glargine Up titration vs Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes. JAMA. 2016;315(9):
25 Effect of Glargine Up Titration vs. Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial Lingvay I, et al. Effect of Glargine Up titration vs Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes. JAMA. 2016;315(9): Effect of Glargine Up Titration vs. Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial Lingvay I, et al. Effect of Glargine Up titration vs Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes. JAMA. 2016;315(9):
26 Prandial Options to Advance Basal Glargine Therapy: Testing Lixisenatide Plus Basal Versus Glulisine Either as Basal Plus or Basal Bolus in Type 2 Diabetes: The GetGoal Duo 2 Trial Glargine Lixisenatide / A1c 7.2% Symptomatic Hypoglycemia = 107 Glargine Optimization A1c improved from 8.5 to 7.9% Glargine Glulisine Daily / metformin Glargine Glulisine 3x daily / metformin A1c 7.2% Symptomatic Hypoglycemia = 140 (P = 0.01 vs. Lixi) A1c 7.0% Symptomatic Hypoglycemia = 154 (P = vs. Lixi) 12 Weeks 26 Weeks 26
27 Dulaglutide Glargine: AWARD 9 Trial Presented at 76 th American Diabetes Association Scientific Sessions A1c reduction Fasting Blood Sugar (mg/dl) Weight Change (kg) Dulaglutide 1.5 mg glargine 1.44% Placebo glargine 0.67% Pozzilli P. Improved Glycemic Control and Weight Loss with Once Weekly Dulaglutide vs. Placebo, Both Added to Titrated Daily Glargine in Type 2 Diabetes Paitients (AWARD 9). Presented at the 2016 American Diabetes Association Scientific Session June th, Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro (Harmony 6) 26 week Study: Randomized, open label, active controlled trial Once weekly albiglutide vs thrice daily insulin lispro added to titrated once daily glargine Oral agents metformin and or pioglitazone could be continued Rosenstock J. et al. Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro. Diabetes Care 2014;37:
28 Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro (Harmony 6) ± pioglitazone and Glargine Optimization Albiglutide 30/50 mg plus glargine/oad s 285 pts 3x daily prandial Lispro glargine/oad s 281 pts A1c = 0.82% Weight Change = 0.7kg Hypoglycemia = 0.9 events/pt/yr A1c = 0.66% Weight Change = 0.8kg Hypoglycemia = 2.3 events/pt/yr 4 8 Weeks 26 Weeks 8 Week Follow up Rosenstock J. et al. Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro. Diabetes Care 2014;37: Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro (Harmony 6) Rosenstock J. et al. Advancing Basal Replacement in Type 2 Diabetes Inadequately Controlled with Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP 1 Receptor Agonist, Versus Thrice Daily Prandial Lispro. Diabetes Care 2014;37:
29 Basal /GLP 1 Powerful new approach to patients with T2DM Effective A1c reduction Less hypoglycemia exposure Potential for weight loss Basal /GLP 1 Agonist Patient Profile Patient with T2DM Has tried a number of oral agents/basal insulin Possibly at hypoglycemic risk No Hx of pancreatitis/mtc/men 2 Renal Status acceptable/stable No Hx of gastroparesis/severe GI disturbance 29
30 Summary: Type 2 Diabetes Mellitus has grown to epidemic proportions The landscape of diabetes medications continues to expand Opportunities for improved control of the disease state with fewer side effects and the potential for reduction of CV risk are growing Combination therapy with newer agents that provide powerful synergy for our patients has the potential to change the landscape of Type 2 Diabetes management. 30
Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationClinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018
Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY
More informationcontinuing education for pharmacists
continuing education for pharmacists 2016 AACE/ACE Guidelines on Type 2 Diabetes Management and New Glycemic Control Agents Amanda R. Kriesen, R.Ph., PharmD, and Erin Bastick, R.Ph., PharmD Volume XXXV,
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationAntidiabetic Agents CHAPTER BIGUANIDES
ajt/shutterstock, Inc. CHAPTER 2 Antidiabetic Agents Charles Ruchalski, PharmD, BCPS BIGUANIDES For newly diagnosed patients with type 2 diabetes, the biguanide metformin is the drug of choice for initial
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More information2018 Diabetes Summit Managing Diabetes: An Art and a Science
2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationHealthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS
Healthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS Table of Contents Introduction 3 Monitoring Your Diabetes 7 Medications 11 Problem Solving 24 Healthy Eating with Diabetes 26 Managing Sick Days
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationGlycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University
Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 None Disclosures Learning Objectives Understand the
More informationManaging Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM
Managing Complex Diabetes Cases: Medication Update Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM clevesqu@mdanderson.org Objectives Describe how each diabetes medication class is used to treat diabetes Differentiate
More informationNew Medications and Prescribing Methods for Diabetic Patients
New Medications and Prescribing Methods for Diabetic Patients Jeffrey Stroup, PharmD, BCPS, FCCP Professor of Medicine Oklahoma State University Center for Health Sciences Department of Internal Medicine
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationDrug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4
Drug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4 OVERVIEW Characteristic Type 1 DM (10%) Type 2 DM (90%) Formerly known as Juvenile; Insulin-dependent Adult onset; Non-insulin dependent
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationJeopardy: Update on Diabetes Pharmacotherapy
Jeopardy: Update on Diabetes Pharmacotherapy Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Objectives Describe the mechanism of action
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationObjectives. Why is Glucose Control Important? 11/2/2016. Jeopardy: Update on Diabetes Pharmacotherapy
Jeopardy: Update on Diabetes Pharmacotherapy Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University Chicago College of Pharmacy Objectives Describe the mechanism of action
More informationDiabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)
Diabetes Basics What is Diabetes? Diabetes is a disease in which the pancreas is unable to make insulin or the body is unable to use insulin or both. This leads to high blood sugar levels in the blood.
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More information